Jing Gong

Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide

Hongxia Wang, Ziyuan Song, Yeh‐Hsing Lao et al. · Proceedings of the National Academy of Sciences · 2018 · 269 citations · Full text

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

Courtney D. DiNardo, Andre C. Schuh, Eytan M. Stein et al. · The Lancet Oncology · 2021 · 185 citations

Phase 1B, Hematological Malignancy, Azacitidine Versus Azacitidine +8

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Courtney D. DiNardo, Anthony S. Stein, Eytan M. Stein et al. · Journal of Clinical Oncology · 2020 · 170 citations · Full text

Scaffold-mediated CRISPR-Cas9 delivery system for acute myeloid leukemia therapy

Tzu‐Chieh Ho, Hye Sung Kim, Yumei Chen et al. · Science Advances · 2021 · 112 citations · Full text

Endosomal signaling of delta opioid receptors is an endogenous mechanism and therapeutic target for relief from inflammatory pain

Nestor N. Jiménez-Vargas, Jing Gong, Matthew Wisdom et al. · Proceedings of the National Academy of Sciences · 2020 · 104 citations · Full text